Manager TitleAgeSince
President - 2023-12-13
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap.
23-12-13Issuer sale

Chief Executive Officer

643,595 0.3411%
23-12-13Issuer sale

Chief Operating Officer

474,932 0.2517%
23-12-13Issuer sale

Executive/Senior Manager

1,747 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +0.73%+9.14%+76.18%+119.90% 25.57B
Weighted average by Cap. +0.62%+8.71%+86.69%+140.75%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock